Drug Discovery, Pharmaceuticals & Cannabis Testing


Retention Modelling to Accelerate and Optimise Methods Development of Biomolecules


The growing interest in biopharmaceuticals is a trend consistent over the past few years. Biopharmaceuticals are structurally complex and pose numerous challenges in drug development. Globally, R&D companies are working to combat the complicated drug analysis necessary for large molecules, while trying to reduce laborious method development.


Retention modelling has proven to be a successful technique in accelerating method development and optimisation. Pharmaceutical companies (such as Novo Nordisk and Merck) are employing variations of this technique to integrate computer-assisted analysis with screening platforms for their chromatographic modelling.


Their method development strategy typically involves screening a wide range of columns and mobile phases that are known to generate large differences in selectivity. From these, the most promising column and mobile phase are selected, and a retention model is built by conducting a limited number of experiments. The retention model is then applied in silico to find the optimal temperature and gradient, assessing method robustness. In silico modelling is an effective tool to conduct fewer experiments and identify optimal conditions, improving the overall screening outcome and generating robust LC methods.


ACD/Labs’ LC Simulator functionality is used by Novo Nordisk and Merck, as part of their screening process to analyse the most comprehensive set of conditions. From there, they determine the best combinations of columns, stationary phases, and chromatographic techniques most suited for the sample. LC Simulator allows the user to define combined custom gradient and 2nd order temperature models (required for proteins) to find optimal selectivity and a suitable retention gradient. The results show the practicality and ease of use of the workflow and the modelling accuracy is shown to be the same for proteins and small molecules.


More information online: ilmt.co/PL/v1Yn 59745pr@reply-direct.com


Polarimeters Tackle Diffi cult Samples in Sugar, Chemical and Pharmaceutical Industries


Xylem’s Bellingham + Stanley brand has added further capabilities to its ADP600 Series polarimeters. Not only is the instrument capable of measuring to four decimal places (°A) under Peltier temperature controlled conditions across the UV/Vis spectrum, a new addition, the ADS620P, is now able to measure dark sugar solutions in the near infrared wavelength (880 nm) when used with Celite® clarifying agent. The use of Celite negates the traditional but environmentally unfriendly lead acetate clarification method commonly used in the sugar industry.


Further enhancements benefit those wishing to operate with harsh chemicals such as hydrochloric acid (HCl) used as a solvent within the pharmaceutical industry. HCl is aggressive to stainless steel tubes meaning standard XPC tubes can’t be used. New glass tubes with PEEK endcaps are resistant to such solvents and this combined with a new, optional, Hastelloy® encased temperature sensor makes for corrosion free analysis of samples prepared with such harsh substances.


ADP600 Series instruments are available as multiple, dual or single wavelength models, incorporating XPC technology, Xylem’s patented Peltier temperature control system. The combination of precision optics with fast and reliable onboard temperature control, the ADP600 Series of high accuracy polarimeters are well suited to the demanding applications of regulated environments.


All ADP600 Series polarimeters feature a touchscreen experience that is intuitive, secure and compliant with a range of international standards including FDA regulation 21 CFR Part 11. ADP600 Series instruments are also compliant with pharmacopeia (BP/EP/USP/JP) as well as several other norms including relevant ASTM and AOAC methods.


More information online: ilmt.co/PL/NZpk 59855pr@reply-direct.com


Specialist Analysis of Cannabinoids in CBD


Products and Medicinal Cannabis SOCOTEC UK is a cutting-edge laboratory that specialises in the analysis of cannabinoids in CBD products and medicinal cannabis. They can help manufacturers and dispensaries to provide patients with safe and effective medicine by testing for contaminants, such as pesticides and heavy metals, which can be harmful to patients. Terpenes are also an important test for cannabis products. These compounds are responsible for the distinct aromas of different cannabis strains, and they potentially have a wide range of medicinal properties. By analysing the terpene profile of a cannabis sample, SOCOTEC UK can help manufacturers and dispensaries to provide patients with the most effective medicine for their specific needs.


The development of standardised products is another important application of laboratory analysis in the field of medicinal cannabis. This ensures that patients are getting the same medical dosage every time, which is particularly important for those using cannabis to treat serious conditions. Laboratory analysis can help to identify new uses for cannabis. By studying the chemical makeup and interactions of different strains of the plant, scientists may discover new compounds that have medicinal properties. This can lead to the development of new treatments for a wide range of conditions, from chronic pain to mental health disorders.


As more countries legalise medicinal cannabis and an increased number of people turn to it for relief, laboratory analysis will play a crucial role in ensuring that patients have access to safe, effective medicines. SOCOTEC UK is at the forefront of this field, providing state- of-the-art testing and analysis services to manufacturers, dispensaries, and others.


More information online: ilmt.co/PL/d119 59989pr@reply-direct.com


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56